Relationship between the 46/1 haplotype of the JAK2 gene and the JAK2 mutational status and allele burden, the initial findings, and the survival of patients with myelofibrosis

Annals of Hematology

Volumn 93, Issue 5, 2014, Pages 797-802

  Martínez Trillos, Alejandra ^a   Maffioli, Margherita ^a   Colomer, Dolors ^b   Alvarez Larrán, Alberto ^c   Pereira, Arturo ^a   Angona, Anna ^c   Bellosillo, Beatriz ^c   Cervantes, Francisco ^a,b  

^a HOSPITAL CLÍNIC   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c HOSPITAL DEL MAR   (Spain)

Author keywords

JAK2 46 1 haplotype; JAK2 gene; JAK2V617F allele burden; Myelofibrosis; Myeloproliferative neoplasms; Prognosis

Indexed keywords

HEMOGLOBIN; JANUS KINASE 2;

ADULT; AGED; ALLELE; ARTICLE; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; HAPLOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MYELOFIBROSIS; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; FEMALE; GENE FREQUENCY; GENOTYPE; HAPLOTYPES; HEMOGLOBINS; HETEROZYGOTE; HOMOZYGOTE; HUMANS; JANUS KINASE 2; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MUTATION; PHENOTYPE; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; SURVIVAL ANALYSIS; THROMBOCYTHEMIA, ESSENTIAL;

EID: 84898912699     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-013-1989-5     Document Type: Article

References (30)

1. Dameshek W (1951) Some speculations on the myeloproliferative syndromes. Blood 6:372-375
2. James C, Ugo V, Le Couédic JP et al (2005) A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature 434:1144-1148
3. Kralovics R, Passamonti F, Buser AS et al (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779-1790
4. Levine RL, Wadleigh M, Cools J et al (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387-397
5. Baxter EJ, Scott LM, Campbell PJ et al (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054-1061
6. Jones AV, Chase A, Silver RT et al (2009) JAK2 haplotype is a major risk factor for the development of myeloproliferrative neoplasms. Nat Genet 41:446-449
7. Olcaydu D, Harutyunyan A, Jäger R et al (2009) A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet 41:450-454
8. Kilpivaara O, Mukherjee S, Schram AM et al (2009) A germline JAK2 SNP is associated with predisposition to the development of JAK2 (V617F)-positive myeloproliferative neoplasms. Nat Genet 41:455-459
9. Tefferi A, Lasho TL, Patnaik MM et al (2010) JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival. Leukemia 24:105-109
10. Wang J, Xu Z, Liu L et al (2013) JAK2V617F allele burden, JAK2 46/1 haplotype and clinical features of Chinese with myeloproliferative neoplasms. Leukemia 27:1763-1767
11. Guglielmelli P, Biamonte F, Spolverini A et al (2010) Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis. Leukemia 24:1533-1537
12. Tefferi A, Thiele J, Orazi A et al (2007) Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: Recommendations from an ad hoc international expert panel. Blood 110:1092-1097
13. Thiele J, Kvasnicka HM, Boeltken B, Zankovich R, Diehl V, Fischer R (1999) Initial (prefibrotic) stages of idiopathic (primary) myelofibrosis (IMF) - a clinicopathological study. Leukemia 13:1741-1748
14. Wilkins BS, Erber WN, Bareford D et al (2008) Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood 111:60-70
15. Barosi G, Mesa RA, Thiele J et al (2008) Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 22:438-439
16. Cervantes F, Dupriez B, Pereira A et al (2009) A new prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113:2895-3001
17. Wernig G, Mercher T, Okabe R et al (2006) Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 107:4274-4281
18. Kralovics R, Stockton DW, Prchal JT (2003) Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease. Blood 102:3793-3796
19. Bellanné-Chantelot Chaumarel I, Labopin M et al (2006) Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood 108:346-352
20. Campbell PJ (2009) Somatic and germline genetics at the JAK2 locus. Nat Genet 41:385-386
21. Olcaydu D, Skoda RC, Looser R et al (2009) The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera. Leukemia 23:1924-1926
22. Pardanani A, Lasho TL, Finke CM et al (2010) The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status - clinical correlates in a study of 226 consecutive patients. Leukemia 24:110-114
23. Jones AV, Campbell PJ, Beer PA et al (2010) The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms. Blood 115:4517-4523
24. Patnaik MM, Lasho TL, Finke CM et al (2010) MPL mutation effect on JAK2 46/1 haplotype frequency in JAK2V617F-negative myeloproliferative neoplasms. Leukemia 24:859-860
25. Cervantes F, Dupriez B, Passamonti F et al (2012) Improving survival trends in primary myelofibrosis: an international study. J Clin Oncol 30:2981-2987
26. Passamonti F, Cervantes F, Vannucchi A et al (2010) A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the International Working Group for Myeloproliferative Neoplasms Research and Treatment. Blood 115:1703-1708
27. Gangat N, Pardanani A, Hanson CA et al (2011) DIPSS-Plus: a refined dynamic international prognostic scoring system (DIPSS) for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count and transfusion status. J Clin Oncol 29:392-397
28. Vannucchi AM, Lasho TL, Guglielmelli P et al (2013) Mutations and prognosis in primary myelofibrosis. Leukemia 27(9):1861-1869
29. Tefferi A, Lasho TL, Huang J et al (2008) Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia 22:756-761
30. Guglielmelli P, Barosi G, Specchia G et al (2009) Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood 114:1477-1483